Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Daridorexant
Drug ID BADD_D02547
Description Nemorexant is under investigation in clinical trial NCT03101189 (A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects).
Indications and Usage Not Available
Marketing Status investigational
ATC Code Not Available
DrugBank ID DB15031
KEGG ID D11886
MeSH ID C000634383
PubChem ID 91801202
TTD Drug ID Not Available
NDC Product Code 80491-7825; 80491-7850
UNII LMQ24G57E9
Synonyms daridorexant | nemorexant | methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-traizol-2-yl)phenyl)- | ((S)-(2-(5-chloro-4-methyl-1H-benzo(d)imidazol-2-yl)-2-methylpyrrolidin-1-yl) (5 methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone) | ACT-541468
Chemical Information
Molecular Formula C23H23ClN6O2
CAS Registry Number 1505484-82-1
SMILES CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams17.15.02.001; 19.02.03.001--
Agitation17.02.05.012; 19.06.02.001-
Confusional state17.02.03.005; 19.13.01.001-
Depression19.15.01.001-
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007-
Drug ineffective08.06.01.006--
Dry mouth07.06.01.002-
Feeling abnormal08.01.09.014--
Hallucination19.10.04.003-
Hangover08.01.09.018--
Hypersensitivity10.01.03.003-
Insomnia17.15.03.002; 19.02.01.002-
Night sweats08.01.03.031; 23.02.03.006--
Nightmare19.02.03.003--
Sleep paralysis17.15.02.005; 19.02.02.004--
Sleep terror17.15.02.006; 19.02.03.008--
Somnambulism17.15.02.004; 19.02.03.006--
Somnolence17.02.04.006; 19.02.05.003-
Suicidal ideation19.12.01.003-
Restless legs syndrome15.05.03.012; 17.02.07.008--
Unevaluable event08.01.03.051--
Therapeutic product effect incomplete08.06.01.052--
The 1th Page    1    Total 1 Pages